BR100 Decreased By (-0.73%)
BR30 Decreased By (-0.77%)
KSE100 Decreased By (-0.49%)
KSE30 Decreased By (-0.47%)
BECO 5.77 Increased By ▲ 0.46 (8.66%)
BML 53.00 Increased By ▲ 1.42 (2.75%)
BOP 33.99 Increased By ▲ 0.03 (0.09%)
CNERGY 8.11 Decreased By ▼ -0.20 (-2.41%)
DCL 12.20 Increased By ▲ 0.40 (3.39%)
FCCL 52.83 Decreased By ▼ -0.17 (-0.32%)
FCSC 5.07 Increased By ▲ 0.12 (2.42%)
FFL 17.95 Decreased By ▼ -0.20 (-1.1%)
FNEL 1.29 Decreased By ▼ -0.03 (-2.27%)
HUMNL 10.88 Decreased By ▼ -0.12 (-1.09%)
KEL 8.02 Decreased By ▼ -0.12 (-1.47%)
KOSM 5.52 Decreased By ▼ -0.06 (-1.08%)
MLCF 86.51 Decreased By ▼ -1.37 (-1.56%)
NBP 185.16 Decreased By ▼ -2.53 (-1.35%)
PACE 10.58 Decreased By ▼ -0.23 (-2.13%)
PAEL 39.42 Decreased By ▼ -0.65 (-1.62%)
PIAHCLA 26.22 Decreased By ▼ -0.27 (-1.02%)
PIBTL 16.67 Decreased By ▼ -0.09 (-0.54%)
PPL 228.18 Decreased By ▼ -2.19 (-0.95%)
PRL 34.68 Decreased By ▼ -0.36 (-1.03%)
PTC 65.33 Increased By ▲ 0.82 (1.27%)
SEARL 90.13 Increased By ▲ 0.25 (0.28%)
SSGC 26.60 Decreased By ▼ -0.37 (-1.37%)
TELE 8.28 Decreased By ▼ -0.09 (-1.08%)
THCCL 58.50 Decreased By ▼ -0.58 (-0.98%)
TPLP 8.22 Increased By ▲ 0.04 (0.49%)
TREET 24.53 Decreased By ▼ -0.47 (-1.88%)
TRG 69.71 Decreased By ▼ -0.92 (-1.3%)
WAVES 9.94 Decreased By ▼ -0.07 (-0.7%)
WTL 1.28 Decreased By ▼ -0.01 (-0.78%)
Topic

US FDA

US FDA expected to authorize Pfizer vaccine for 12-15-year-olds soon

US FDA expected to authorize Pfizer vaccine for 12-15-year-olds soon

Published 05 May, 2021 06:26pm
  • The approval is highly anticipated after the drugmaker said in March the vaccine was found to be safe, effective and produced a robust antibody responses in 12- to 15-year-olds in a clinical trial.
  • The vaccine has already been cleared in the United States for those aged 16 and above.
Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

Published 16 Apr, 2021 05:45pm
  • The request made to the US Food and Drug Administration is not due to any new safety issues, but in response to the new variants in the country that could be resistant to bamlanivimab when used alone, the drugmaker said in a statement.
  • Hospitals with bamlanivimab supply should now order etesevimab to pair with it, Lilly said.
Loading...